The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“Both mutations are located within the L3 loop of p53.(11) The R248 residue is in direct physical contact with the minor groove of DNA and has been traditionally called a ‘contact’ mutation.”
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“For the human analysis, we used the latest p53 IARC database (version R15) that contains extensive clinical information regarding tumor onset in carriers of p53 germline mutations.(19) All Li–Fraumeni patients with large deletions, nonsense, splicing and frameshift mutations were considered ‘null/þ ’ in this analysis.”
MethodMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Mutant p53 drives invasion by promoting integrin recycling
Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796
Mutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells
Cicalese, A., Bonizzi, G., Pasi, C. E., Faretta, M., Ronzoni, S., Giulini, B., Brisken, C., Minucci, S., Di Fiore, P. P., & Pelicci, P. G. (2009) · Cell · doi:10.1016/j.cell.2009.06.048 · Cited by 696
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 666
Vaseva, A. V., & Moll, U. M. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.10.005 · Cited by 618
Self-citationRescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature Reviews Cancer · doi:10.1038/35094077 · Cited by 568
p53 Regulates Hematopoietic Stem Cell Quiescence
Liu, Y., Elf, S. E., Miyata, Y., Sashida, G., Liu, Y., Huang, G., Di Giandomenico, S., Lee, J. M., Deblasio, A., Menendez, S., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2008.11.006 · Cited by 547
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., McGregor, J. M., Harwood, C. A., Yulug, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 515
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 439
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
Kogan, S. C., Ward, J. M., Anver, M. R., Berman, J. J., Brayton, C., Cardiff, R. D., Carter, J. S., de Coronado, S., Downing, J. R., Fredrickson, T. N., et al. (2002) · Blood · doi:10.1182/blood.v100.1.238 · Cited by 418
p53 suppresses the self-renewal of adult neural stem cells
Meletis, K., Wirta, V., Hede, S.-M., Nistér, M., Lundeberg, J., & Frisén, J. (2006) · Development · doi:10.1242/dev.02208 · Cited by 413
Tumors associated with p53 germline mutations: a synopsis of 91 families.
Kleihues, P., Schäuble, B., Hausen, A. Z., Estève, J., & Ohgaki, H. (1997) · Europe PMC (PubMed Central) · Cited by 411
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 357
Bethesda proposals for classification of lymphoid neoplasms in mice
Morse, H. C. (2002) · Blood · doi:10.1182/blood.v100.1.246 · Cited by 342
Kikushige, Y., Ishikawa, F., Miyamoto, T., Shima, T., Urata, S., Yoshimoto, G., Mori, Y., Iino, T., Yamauchi, T., Eto, T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.029 · Cited by 317
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230
A common gain of function of p53 cancer mutants in inducing genetic instability
Liu, D. P., Song, H., & Xu, Y. (2010) · Oncogene · doi:10.1038/onc.2009.376 · Cited by 219
Links between mutant p53 and genomic instability
Hanel, W., & Moll, U. M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23400 · Cited by 216
Self-citationTargeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function
de Vries, A., Flores, E. R., Miranda, B., Hsieh, H.-M., van Oostrom, C. T. M., Sage, J., & Jacks, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052713099 · Cited by 207
Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200
The Molecular Characterization of the Fetal Stem Cell Marker AA4
Petrenko, O., Beavis, A., Klaine, M., Kittappa, R., Godin, I., & Lemischka, I. R. (1999) · Immunity · doi:10.1016/s1074-7613(00)80068-0 · Cited by 161
Hsiao, M., Low, J., Dorn, E., Ku, D., Pattengale, P. K., Yeargin, J., & Haas, M. (1994) · PubMed Central · Cited by 135
Luo, J., Yang, Q., Tong, W., Hergenhahn, M., Wang, Z., & Hollstein, M. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204080 · Cited by 135
Cowell, J. K., Matsui, S., Wang, Y. D., LaDuca, J. R., Conroy, J. M., McQuaid, D., & Nowak, N. J. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2003.09.012 · Cited by 56
Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells
Yoshikawa, K., Hamada, J., Tada, M., Kameyama, T., Nakagawa, K., Suzuki, Y., Ikawa, M., Hassan, N. M. M., Kitagawa, Y., & Moriuchi, T. (2010) · Biomedical Research · doi:10.2220/biomedres.31.401 · Cited by 55
Haines, B. B., Ryu, C. J., Chang, S. S., Protopopov, A. I., Luch, A., Kang, Y. H., Draganov, D., Fragoso, M. F., Paik, S. G., Hong, H. J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.004 · Cited by 42
Bertout, J. A., Patel, S. A., Fryer, B. H., Durham, A. C., Covello, K. L., Olive, K. P., Goldschmidt, M. H., & Simon, M. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4223 · Cited by 36
Lee, M. K., & Sabapathy, K. (2008) · Journal of Cell Science · doi:10.1242/jcs.022822 · Cited by 34
Myc, Aurora Kinase A, and mutant p53R172H co-operate in a mouse model of metastatic skin carcinoma
Torchia, E. C., Caulín, C., Acín, S., Terzian, T., Kubick, B. J., Box, N. F., & Roop, D. R. (2011) · Oncogene · doi:10.1038/onc.2011.441 · Cited by 29
Trková, M., Foretová, L., Kodet, R., Hedvičáková, P., & Sedláček, Z. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00031-1 · Cited by 17
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Why are there hotspot mutations in the TP53 gene in human cancers?
Baugh, E. H., Ke, H., Levine, A. J., Bonneau, R. A., & Chan, C. S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.180 · Cited by 607
Metadata
- Authors
- Hanel, W., Marchenko, N., Xu, S., Xiaofeng Yu, S., Weng, W., & Moll, U.
- Venue
- Cell Death & Differentiation
- Published
- 2013-03-29
- Volume
- 20
- Issue
- 7
- Pages
- 898-909
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W1985271346
- Cited by
- 283
- References
- 38
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.